Anti-RBD-3 antibody (EY6A)

Reference: PTXCOV-A551
size

100µg

Isotype

IgG1

Brand

Product type

Clonality

Product nameAnti-RBD-3 antibody (EY6A)
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity85%
BufferPBS, pH7,5
FormLiquid
Delivery conditionBlue ice (+4°C)
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteogenix
Aliases /SynonymsEY6A antibody
ReferencePTXCOV-A551
NoteFor research use only. Not suitable for in vitro diagnostic and human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRBD domain- SARS-CoV2 Spike protein

Description of Anti-RBD-3 antibody (EY6A)

General information on Anti-RBD-3 antibody

Anti-CoV-RBD Antibody is a fully human IgG immunoglobulin designed to target the receptor binding domain (RBD) of the novel pandemic SARS-CoV-2 coronavirus. When developing therapeutic antibodies for COVID-19, targeting this specific area has unique advantages. RBD is responsible for the recognition and binding of the specific cell surface marker ACE2 (Angiotensin Converting Enzyme 2). This interaction further leads to proteolytic tip cleavage, which exposes the S2 subunit and initiates the formation of the central membrane composite complex. Antibodies that can block this initial interaction are called neutralizing antibodies (NAbs). These specific and rare antibodies are at the forefront of COVID-19 treatment because they can prevent infection with SARS-CoV-2 at the earliest stage.
This novel antibody was obtained using phage display technology (i.e., biological scanning) to screen a diverse library of human COVID-19 antibodies (LiAb-SFCOVID-19 *) and express by RBD recombination as the desired target. It takes advantage of the immune pool generated in patients infected with COVID-19. In addition, the specificity and affinity of the newly developed molecules were tested on the ELISA platform. Stability and ease of production are further confirmed by consistently obtaining high yields in XtenCHO ™, which is a transient mammalian system based on the CHO variant.
In addition, by indirect detection and analysis: SARS-CoV-2 replaced the viral neutralization kit, the neutralizing activity of the R3P2-A2 antibody was confirmed in vitro. This analysis is based on the principle that the candidate antibody and ACE2 directly compete in the obligatory pocket of RBD. This antibody and other similar products can be used as effective researchers to detect the presence of SARS-CoV-2 in many samples in an ELISA test, and can better understand the mechanism of infection of the novel coronavirus.

SDS-PAGE for Anti-RBD-3 antibody

Anti-RBD-3 antibody (EY6A), on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Anti-RBD-3 antibody (EY6A)”

Your email address will not be published. Required fields are marked *

Related products

Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 180€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products